Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014

Introduction: Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment. Resistance to INH may increase the likelihood of negative treatment outcome. Aim: We aimed to determine the impact of INH mono-resistance on TB treatment outcome in the European Union/European Economic Area and to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Karo, Basel, Kohlenberg, Anke, Hollo, Vahur, Duarte, Raquel, Fiebig, Lena, Jackson, Sarah, Kearns, Cathriona, Ködmön, Csaba, Korzeniewska-Kosela, Maria, Papaventsis, Dimitrios, Solovic, Ivan, van Soolingen, Dick, van der Werf, Marieke J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440580/
https://www.ncbi.nlm.nih.gov/pubmed/30914081
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.12.1800392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440580/
https://www.ncbi.nlm.nih.gov/pubmed/30914081
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.12.1800392

Ejemplares similares